Anne S Tsao

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma
    Anne S Tsao
    Department of Thoracic and Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX Electronic address
    Ann Diagn Pathol 18:140-5. 2014
  2. ncbi request reprint Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma
    Anne S Tsao
    Department of Thoracic, Head, and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX Electronic address
    Clin Lung Cancer 15:197-201. 2014
  3. pmc Phase II study of TAS-106 in patients with platinum-failure recurrent or metastatic head and neck cancer and nasopharyngeal cancer
    Anne Tsao
    Department of Thoracic and Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Med 2:351-9. 2013
  4. doi request reprint Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial
    Anne S Tsao
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center Houston, Texas 7030, USA
    J Thorac Oncol 8:658-61. 2013
  5. doi request reprint The importance of molecular profiling in predicting response to epidermal growth factor receptor family inhibitors in non-small-cell lung cancer: focus on clinical trial results
    Anne S Tsao
    Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lung Cancer 14:311-21. 2013
  6. doi request reprint Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial
    Anne S Tsao
    Department of Thoracic Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Thorac Oncol 7:1645-52. 2012
  7. doi request reprint Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma
    Anne S Tsao
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Thorac Oncol 6:2104-11. 2011
  8. pmc Immunohistochemical overexpression of platelet-derived growth factor receptor-beta (PDGFR-β) is associated with PDGFRB gene copy number gain in sarcomatoid non-small-cell lung cancer
    Anne S Tsao
    Department of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lung Cancer 12:369-74. 2011
  9. pmc A practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria
    Anne S Tsao
    Department of Thoracic and Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Thorac Oncol 6:598-601. 2011
  10. doi request reprint Neoadjuvant and intrapleural therapies for malignant pleural mesothelioma
    Anne S Tsao
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Clin Lung Cancer 10:36-41. 2009

Detail Information

Publications29

  1. ncbi request reprint Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma
    Anne S Tsao
    Department of Thoracic and Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX Electronic address
    Ann Diagn Pathol 18:140-5. 2014
    ..09-0.72], P=.0096) and improved overall survival (HR 0.32 [95% CI 0.11-0.89], P=.029). PDGFRB CNG >40% of MPM tumor cells is a potential prognostic biomarker for surgery and may identify a unique population of mesothelioma patients. ..
  2. ncbi request reprint Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma
    Anne S Tsao
    Department of Thoracic, Head, and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX Electronic address
    Clin Lung Cancer 15:197-201. 2014
    ..We conducted a phase I trial of cisplatin/pemetrexed/imatinib mesylate, an oral platelet-derived growth factor receptor (PDGFR) inhibitor, in chemonaive patients with malignant pleural mesothelioma (MPM)...
  3. pmc Phase II study of TAS-106 in patients with platinum-failure recurrent or metastatic head and neck cancer and nasopharyngeal cancer
    Anne Tsao
    Department of Thoracic and Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Med 2:351-9. 2013
    ..There was no anti-tumor efficacy seen with TAS-106 monotherapy. Future studies will focus on TAS-106 combinations and mechanisms of drug resistance. ..
  4. doi request reprint Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial
    Anne S Tsao
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center Houston, Texas 7030, USA
    J Thorac Oncol 8:658-61. 2013
    ..Herein, we report the clinical and biomarker results of the phase II vandetanib trial...
  5. doi request reprint The importance of molecular profiling in predicting response to epidermal growth factor receptor family inhibitors in non-small-cell lung cancer: focus on clinical trial results
    Anne S Tsao
    Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lung Cancer 14:311-21. 2013
    ..The identification of these and other molecular determinants is driving the development of novel therapies designed to achieve improved clinical outcomes in patients...
  6. doi request reprint Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial
    Anne S Tsao
    Department of Thoracic Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Thorac Oncol 7:1645-52. 2012
    ..Here we report outcomes (survival and toxicity) of elderly patients on the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial...
  7. doi request reprint Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma
    Anne S Tsao
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Thorac Oncol 6:2104-11. 2011
    ..Baseline tumor specimens, serum, and perfusion computed tomography (CT) scans were obtained for supportive evaluation...
  8. pmc Immunohistochemical overexpression of platelet-derived growth factor receptor-beta (PDGFR-β) is associated with PDGFRB gene copy number gain in sarcomatoid non-small-cell lung cancer
    Anne S Tsao
    Department of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lung Cancer 12:369-74. 2011
    ..Further studies are warranted to determine whether PDGFR-b is a feasible therapeutic target in this population...
  9. pmc A practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria
    Anne S Tsao
    Department of Thoracic and Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Thorac Oncol 6:598-601. 2011
    ..With this consistency, we may be able to better estimate the prognosis and response to therapy. With greater utilization, we will be able to better understand the biology of MPM...
  10. doi request reprint Neoadjuvant and intrapleural therapies for malignant pleural mesothelioma
    Anne S Tsao
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Clin Lung Cancer 10:36-41. 2009
    ..The following review discusses the latest results in neoadjuvant and intrapleural therapies in malignant pleural mesothelioma...
  11. doi request reprint Malignant pleural mesothelioma
    Anne S Tsao
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030, USA
    J Clin Oncol 27:2081-90. 2009
    ..In addition, there are controversial issues, such as the role of extrapleural pneumonectomy, adjuvant radiotherapy, and use of intensity-modulated radiotherapy versus hemithoracic therapy that will also be addressed in this manuscript...
  12. ncbi request reprint Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion
    Anne S Tsao
    Department of Thoracic Head and Neck Medical Oncology, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 432, Houston, TX 77030, USA
    Mol Cancer Ther 6:1962-72. 2007
    ..02). Activated c-Src may play a role in survival, metastasis, and invasion of MPM, and targeting c-Src may be an important therapeutic strategy...
  13. ncbi request reprint Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer
    Anne S Tsao
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:2428-36. 2006
    ..The purpose of the current study was to determine whether smoking during chemotherapy or chemoradiation therapy for nonsmall cell lung cancer (NSCLC) affects treatment outcome...
  14. ncbi request reprint Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer
    Anne S Tsao
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    J Thorac Oncol 1:231-9. 2006
    ..The authors sought to define clinicopathologic features associated with mutations of the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancer (NSCLC)...
  15. pmc The role of consolidation therapy for stage III non-small cell lung cancer with persistent N2 disease after induction chemotherapy
    Arya Amini
    Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Ann Thorac Surg 94:914-20. 2012
    ..We assessed the role of consolidative therapies (postoperative radiation therapy and chemotherapy) for such patients...
  16. ncbi request reprint Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck
    Anne S Tsao
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 24:4163-9. 2006
    ....
  17. ncbi request reprint Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program
    Sheeba K Thomas
    Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lung Cancer 7:326-31. 2006
    ..The primary objective of this retrospective study was to investigate the potential role of East Asian ethnicity or origin in predicting response to gefitinib in advanced-stage non-small-cell lung cancer (NSCLC)...
  18. ncbi request reprint Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma
    Daniel R Gomez
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77054, USA
    J Thorac Oncol 8:238-45. 2013
    ....
  19. ncbi request reprint Chemoprevention of cancer
    Anne S Tsao
    Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    CA Cancer J Clin 54:150-80. 2004
    ..Future directions in the field of chemoprevention will be proposed that are based on recently acquired mechanistic insight into carcinogenesis...
  20. ncbi request reprint Extended surgical staging for potentially resectable malignant pleural mesothelioma
    David C Rice
    Department of Thoracic and Cardiovascular Surgery, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Ann Thorac Surg 80:1988-92; discussion 1992-3. 2005
    ..We evaluated the role of extended surgical staging procedures, which generally includes a combination of laparoscopy, peritoneal lavage, and mediastinoscopy, to more precisely stage patients with MPM...
  21. ncbi request reprint Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions
    Anne S Tsao
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Prev Res (Phila) 2:931-41. 2009
    ..Higher doses of GTE may improve short-term (12-week) OPL outcome. The present results support longer-term clinical testing of GTE for oral cancer prevention...
  22. pmc Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC)
    Farshid Dayyani
    Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Head Neck Oncol 2:15. 2010
    ..HPV is important in a subset of HNSCC. Our meta-analysis determined the clinical characteristics of HPV-related HNSCC...
  23. ncbi request reprint Increased phospho-AKT (Ser(473)) expression in bronchial dysplasia: implications for lung cancer prevention studies
    Anne S Tsao
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer Epidemiol Biomarkers Prev 12:660-4. 2003
    ..Given its role as a mediator of malignant transformation, p-AKT should be investigated as a potential target in future lung cancer prevention studies...
  24. ncbi request reprint Imatinib mesylate causes hypopigmentation in the skin
    Anne S Tsao
    Medical Oncology Fellowship Program, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:2483-7. 2003
    ..In clinical trials with imatinib mesylate, common side effects of nausea, emesis, diarrhea, periorbital edema, fluid retention, and myelosuppression have been documented...
  25. ncbi request reprint Nonsmall-cell lung cancer: chemoprevention studies
    Daniel D Karp
    MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Semin Thorac Cardiovasc Surg 15:405-20. 2003
    ....
  26. ncbi request reprint C-kit receptor expression in acute leukemias-association with patient and disease characteristics and with outcome
    Anne S Tsao
    MD Anderson Cancer Center, University of Texas, 1515 Holcombe Boulevard, P O Box 428 Houston, TX 77030, USA
    Leuk Res 28:373-8. 2004
    ..However, after accounting for these covariates, multivariate analysis indicates that higher c-kit expression predicts higher CR rates, although there was no effect on DFS in CR...
  27. ncbi request reprint Phase I evaluation of docetaxel and topotecan for patients with advanced solid tumors
    Anne S Tsao
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:2240-5. 2004
    ..The authors administered a combination of docetaxel and topotecan with granulocyte-colony-stimulating factor (G-CSF) support in a Phase I study to define the maximum tolerated dose (MTD) of this regimen...
  28. ncbi request reprint STI-571 in chronic myelogenous leukaemia
    Anne S Tsao
    Department of Bioimmunotherapy, M D Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 119:15-24. 2002
  29. ncbi request reprint Surgery: Future directions in multimodality therapy for NSCLC
    Anne S Tsao
    Department of Thoracic and Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Nat Rev Clin Oncol 7:10-2. 2010
    ..Albain and colleagues recently demonstrated that trimodality therapy with lobectomy had clinical benefit for patients with pathologic nodal N2 stage III nSclc. we discuss the trial and its implications for future lung cancer therapy...